

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT MENINGOCOCCAL DISEASE

The purpose of this resolution is to update the eligible groups for meningococcal vaccination to include children aged 9-23 months of age at increased risk of meningococcal disease, to update the intervals for booster doses, and to add information about the meningococcal polysaccharide vaccine back into the VFC resolution.

VFC resolution 10/10-1 is repealed and replaced by the following:

Eligible groups

- Children aged 9 months through 10 years who are at increased risk for meningococcal disease, including
 - children who have complement deficiencies (e.g., C5-C9, properdin, factor H, or factor D);
 - children with HIV infection;
 - travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic;
 - children who are who are part of an outbreak of a vaccine-preventable serogroup.
- Children aged 2 through 10 years who have anatomic or functional asplenia
- All children aged 11 through 18 years

Recommended Vaccination Schedule and Intervals (1)

Age	Subgroup	Primary Vaccination	Booster Dose
9 through 23 months of age, with high risk conditions	Children with complement deficiencies;	Two doses of MCV4, three months apart	If first dose received at age 9 months through 6 years and remain at increased risk for meningococcal disease, should receive an additional dose of MCV4 three years after primary vaccination. Boosters should be repeated every five years thereafter.
	Children with HIV, if another indication for vaccination exists	Two doses of MCV4, three months apart	
	All others in this age group recommended for vaccination (travelers to the Meningitis Belt, ect)	Two doses of MCV4 , three months apart (infants receiving the vaccine prior to travel can receive the doses as early as two months apart)	
2 through 18 years of age, with high risk conditions (2)	Children with complement deficiencies; functional or anatomic asplenia;	Two doses of MCV4 , two months apart	If first dose received at age 7 years or older and remain at increased risk for meningococcal disease, should receive an additional dose of MCV4 five years after primary vaccination. Boosters should be repeated every five years thereafter.
	Children with HIV, if another indication for vaccination exists	Two doses of MCV4 , two months apart	
	All others in this age group recommended for vaccination (travelers to the Meningitis Belt, etc)	Single dose of MCV4	
All other children 11-18 years of age		Routine vaccination with MCV4 at ages 11 through 12 years	If vaccinated at age 11 through 12 years, should receive a one-time booster dose at age 16 years If vaccinated at age 13 through 15 years, should receive a one-time booster dose at age 16 through 18 years

- (1) At the time of this resolution, there are currently two licensed MCV4 products. One product, Menactra ®, is manufactured by sanofi pasteur and is licensed for use in persons aged 9 months through 55 years of age. The second product, Menveo ®, is manufactured by Novartis Vaccines and Diagnostics, Inc. and is licensed for use in persons aged 2 through 55 years of age. A meningococcal polysaccharide vaccine is also available. This product is licensed for use in persons 2 years of age and older and may be used when meningococcal conjugate vaccine is unavailable or contraindicated.
- (2) Includes children who have complement deficiencies (e.g., C5-C9, properidin, factor H, or factor), anatomic or functional asplenia, and children with HIV infection; travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic; and children who are who are part of a community outbreak of a vaccine-preventable serogroup.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

[If an ACIP recommendation or notice regarding meningococcal vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: June 22, 2011

This document can be found on the CDC website at:
<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf>